Categories: News

Nephros to Present at the Q1 Virtual Investor Summit

SOUTH ORANGE, N.J., March 16, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that Andy Astor, Chief Executive Officer, has been invited to present at the Q1 Virtual Investor Summit. The conference will take place on March 23-25, 2021, and includes a Nephros company presentation and Q&A at 2:30 p.m. ET on March 23.

To register to attend the live presentation click the following link:

https://zoom.us/webinar/register/WN_rBYVMLR8RP6-JbQsQa1qOQ

To request a complimentary investor registration and 1-to-1 meeting with Nephros, please visit the conference website at www.investorsummitgroup.com.

About Nephros

Nephros is a leading water technology company in medical and commercial water purification and pathogen detection, headquartered in the USA. Our diverse team of passionate employees are dedicated to advancing point-of-use water safety through education, product solutions, and emergency outbreak response management.

For more information about Nephros, please visit www.nephros.com.

About The Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting small-cap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors. 

Conference Contact: 
Brittney Blocker at brittney@investorsummitgroup.com

Investor Relations Contact:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com
www.pcgadvisory.com

Company Contact:
Andy Astor, President and CEO
Nephros, Inc.
(201) 345-0824
andy@nephros.com
www.nephros.com

Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

11 minutes ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

11 minutes ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

11 minutes ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

11 minutes ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

11 minutes ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

11 minutes ago